EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database

Keeirah Hiertika Raguram, Manroop Sidhu, Mohammad Ali Omrani iD, Bala Swetha Baskaran, Niaz Chalabianloo, Manik Chhabra, Hugues Sampasa-Kanyinga, Flory Tsobo Muanda iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag083 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Keeirah Hiertika Raguram und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Fluoroquinolones, Anti-Bacterial Agents, Panic Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Fluoroquinolones are linked with increased risk of CNS adverse events, such as anxiety and depression. Recently, case reports have linked fluoroquinolone use and panic attacks. However, current evidence exploring the link between fluoroquinolone use and panic attacks remains limited and requires investigation for safe use. To systematically review the literature on fluoroquinolone use and the risk of panic attacks, and to study this association by comparing fluoroquinolones with other antibiotics using the FDA Adverse Event Reporting System (FAERS) database.

Methods

MEDLINE and Embase databases were searched to identify relevant studies for systematic review. Active-comparator restricted disproportionality analyses using FAERS (2004Q1-2024Q4) were performed for ciprofloxacin, levofloxacin, and moxifloxacin compared to azithromycin and trimethoprim/sulfamethoxazole. Reporting odds ratios (ROR), proportional reporting ratios, adjusted ROR for potential confounders, and Bayesian analyses were conducted to detect safety signals for MedDRA term ‘panic attack’.

Results

The systematic review identified 12 studies (4 clinical trials, 8 publications describing 11 case reports), with the prevalence of panic attacks ranging between 0.46% and 1.76% in trials. Disproportionality analysis showed that, compared to azithromycin, fluoroquinolones were associated with a 6-fold increase in reports of panic attacks and a 12-fold increase compared to trimethoprim/sulfamethoxazole. Results were consistent across Bayesian analyses.

Conclusion

The findings suggest an association between fluoroquinolones and increased risk of panic attacks, underscoring the need for validation through pharmacoepidemiological studies. Due to reliance on spontaneous reports, causal relationships cannot be determined for clinical recommendations. These results offer insights for research on CNS safety profiles of fluoroquinolones.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesAnti-Bacterial AgentsPanic DisorderHumansUnited StatesAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationDatabases, Factual

Substanzen

FluoroquinolonesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.
  • ICES Western, Kidney, Dialysis & Transplantation Research Program, London, Ontario, Canada.
  • Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada.
  • Healthy Active Living and Obesity Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.

ORCID-Profile: Mohammad Ali Omrani, Flory Tsobo Muanda

Zitieren

APA

Raguram, K. H., Sidhu, M., Omrani, M. A., Baskaran, B. S., Chalabianloo, N., Chhabra, M., Sampasa-Kanyinga, H., & Muanda, F. T. (2026). Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag083

Vancouver

Raguram KH, Sidhu M, Omrani MA, Baskaran BS, Chalabianloo N, Chhabra M, et al. Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag083

BibTeX
@article{Raguram2026,
  author = {Raguram, Keeirah Hiertika and Sidhu, Manroop and Omrani, Mohammad Ali and Baskaran, Bala Swetha and Chalabianloo, Niaz and Chhabra, Manik and Sampasa-Kanyinga, Hugues and Muanda, Flory Tsobo},
  title = {Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag083}
}
Kostenlos starten →